8-KLeadership ChangesExhibits & Filings

Elevance Health, Inc. 8-K Report, Executive Changes (Oct 1, 2019)

Filed October 1, 2019For Securities:ELV

Summary

Elevance Health, Inc. (formerly Anthem, Inc.) announced a significant governance update through an 8-K filing on October 1, 2019. The primary focus of this report is the election of Ryan Schneider to the company's Board of Directors, effective immediately. Mr. Schneider's appointment is for a term expiring at the 2022 annual shareholder meeting and includes a seat on the critical Audit Committee. This appointment signals a proactive approach by Elevance Health to strengthen its board's expertise, particularly within its audit oversight functions. Investors should note that Mr. Schneider's election is routine, with no undisclosed arrangements or material interests in company transactions. His compensation will follow the standard program for non-employee directors, aligning with industry practices and ensuring financial transparency.

Key Highlights

  • 1Ryan Schneider elected as an independent director to the Board of Directors, effective October 1, 2019.
  • 2Mr. Schneider's term as director will expire at the Company's 2022 annual shareholder meeting.
  • 3Mr. Schneider appointed to the Audit Committee of the Board, enhancing audit oversight.
  • 4No undisclosed arrangements or material interests related to Mr. Schneider's election.
  • 5Director compensation will be in line with the company's standard program for non-employee directors.
  • 6A press release announcing the election is furnished as Exhibit 99.1.

Frequently Asked Questions

Ryan Schneider has been elected as an independent director to the Board of Directors of Elevance Health, effective October 1, 2019. He will serve until the 2022 annual shareholder meeting and has also been appointed to the Audit Committee.

According to the filing, there are no arrangements or understandings between Mr. Schneider and any other person pursuant to which he was elected. He also has no direct or indirect material interest in any transaction that requires disclosure under Regulation S-K.

Mr. Schneider will receive compensation according to Elevance Health's standard compensation program for non-employee directors. This program's details are available in Exhibit 10.7 of the company's Form 10-Q for the quarter ended June 30, 2019.

The appointment of Mr. Schneider to the Audit Committee is significant as it strengthens the board's oversight of financial reporting, internal controls, and the audit process. This can be viewed positively by investors as it indicates a commitment to robust governance and financial integrity.